WORCESTER, Mass., March 25, 2009 (GLOBE NEWSWIRE) -- Anna E. Gluskin, the chairman, president and CEO of Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, was featured this morning on the "C-Suite" segment of FOX Business Network. The segment can be viewed online at www.foxbusiness.com and will be available later today at www.generex.com.
Gluskin and program host Connell McShane discussed Generex's range of products based on the company's proprietary RapidMist(tm) platform technology for drug delivery through the inner lining of the mouth, ensuring that there is no deposit in the lungs. The company's flagship product, Generex Oral-lyn(tm) is an oral insulin spray product for the treatment of Type-1 and Type-2 diabetes, available to patients in India and Ecuador, and recently approved for importation, marketing, distribution, and commercial sale in Lebanon. Generex Oral-lyn(tm) is in Phase III global clinical trials, a preliminary review of which demonstrated positive results. McShane noted that an oral spray is "an easier way for people, certainly, to administer insulin than giving an injection."
Generex has also developed and markets Glucose RapidSpray(tm), an over-the-counter product designed for use early in the onset of a low blood sugar episode; BaBOOM!(tm) Energy Spray, a convenient and great-tasting energy spray alternative to energy drinks; and Crave-NX(tm) 7-Day Diet Aid Spray, clinically tested and designed to quickly curb cravings throughout the day. The company is also developing MetControl(tm), a chewing gum form of the common generic Metformin pill, in clinical trials.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in India and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.